Neurogram

About Neurogram

Neurogram develops an AI-driven platform that analyzes EEG data to identify neuro-biomarkers for neurological diseases, including epilepsy and Alzheimer's. This technology enhances diagnostic accuracy and reduces the time and costs associated with evaluating complex neurological conditions in critical care settings.

Neurogram develops an AI-driven platform that analyzes EEG data to identify neuro-biomarkers for neurological diseases, including epilepsy and Alzheimer's. This technology enhances diagnostic accuracy and reduces the time and costs associated with evaluating complex neurological conditions in critical care settings.

What does Neurogram do?

Neurogram develops an AI-driven platform that analyzes EEG data to identify neuro-biomarkers for neurological diseases, including epilepsy and Alzheimer's. This technology enhances diagnostic accuracy and reduces the time and costs associated with evaluating complex neurological conditions in critical care settings.

Where is Neurogram located?

Neurogram is based in Atlanta, United States.

When was Neurogram founded?

Neurogram was founded in 2021.

Who founded Neurogram?

Neurogram was founded by Daniele De Mari.

  • Daniele De Mari - CEO
Location
Atlanta, United States
Founded
2021
Employees
15 employees
Investors
Starship
N

Neurogram

Neurogram develops an AI-driven platform that analyzes EEG data to identify neuro-biomarkers for neurological diseases, including epilepsy and Alzheimer's. This technology enhances diagnostic accuracy and reduces the time and costs associated with evaluating complex neurological conditions in critical care settings.

Atlanta, United StatesFounded 202115700+ followers4/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Features

  • Neurogram develops an AI-driven platform that analyzes EEG data to identify neuro-biomarkers for neurological diseases, including epilepsy and Alzheimer's. This technology enhances diagnostic accuracy and reduces the time and costs associated with evaluating complex neurological conditions in critical care settings.
This profile is AI-generated and may contain inaccuracies.